Drug Trial Radar · NCT02401971
Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Mar 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
900
Planned (sponsor's estimate)
Start
Aug 2014
Primary completion
Aug 2016
Study completion Aug 2018
Sponsor
- Lead sponsor
- Wang JufengAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The First Affiliated Hospital of Zhengzhou University; Henan Provincial People's Hospital; Second Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Henan University of Science and Technology
- First posted
- Mar 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Recent clinical studies have demonstrated a reduction of irinotecan (CPT-11) gastrointestinal toxicities when the CPT-11 is administered in combination with thalidomide in patients with diagnosis of gastric cancer. The main purpose of this study is to investigate the efficacy and safety of thalidomide and CPT-11 in advanced gastric cancer. The investigators will also manage to find out the possible interactions between CPT-11 pharmacokinetics and thalidomide to explain the previously described gastrointestinal toxicity reduction.
Conditions
- Gastric Cancer
Interventions
ThalidomideDrug
Given orally
CPT-11Drug
Given Ivgtt
Primary outcomes
What the sponsor says the trial is designed to measure.
- time to progression(TTP)Time frame: up to 2 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.